In this study, safety and effects of IPM001 vaccine on human hepatocellular carcinoma are going to be investigated, IPM001 is a neoantigen/tumor-specific antigen sensitized autoimmune cell injection

Inclusion Criteria:

• understand and voluntarily sign a written informed consent;
• Age: from 18 to 75 years, No restriction on gender;
• Patients must have primary hepatocellular carcinoma;
• Clinical stage: stage Ia~III a;
• Child-pugh score ≤7;
• HLA-A02 and consistent with ≥1 NeoAg or ≥2 aeTSA peptide bank;
• ECOG PS score: 0~2;
• Laboratory values as follow:
• White blood cell count ≥ 3×109/L; Neutrophils: more than 1.5 × 109/L; Hemoglobin: more than 85g/L; Platelets: more than 5 × 1010/L; Total bilirubin:≤2 × ULN; Serum AST(GOT) and ALT(GPT)≤2.5 × ULN; Albumin ≥3.0 g/dL (30 g/L); Serum creatinine: less than 1.5 × ULN; Coagulation time was basically normal, PT extension ≤4s; No serious cardiopulmonary disease;
• Blood collection body weight: male > 50 kg, female > 45 kg;
• No obvious hereditary diseases;
• Expected survival: more than 6 months;

Exclusion Criteria:

• Patient has known distant organ metastasis;
• Suffer from lymphoma or leukemia or MDS (myelodysplastic syndrome), etc.;
• Woman be pregnant or lactating;
• Suffer from mental or neurological diseases that are resistant to control;
• The investigator judges that it is not suitable to participate in this clinical research (such as poor compliance, etc.);
• Patients infected with human immunodeficiency virus (commonly known as AIDS) or Treponema pallidum (commonly known as syphilis);
• Patients with a history of other malignant tumors in the past 5 years;
• Organ transplantation or Myelosuppression;
• History of drug abuse or alcohol abuse;